Viewing Study NCT00004431



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004431
Status: COMPLETED
Last Update Posted: 2015-03-25
First Post: 1999-10-18

Brief Title: Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia
Sponsor: University of Pittsburgh
Organization: FDA Office of Orphan Products Development

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2000-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES I Evaluate the efficacy of L-baclofen in patients with refractory trigeminal neuralgia

II Evaluate the safety and tolerance of L-baclofen in these patients
Detailed Description: PROTOCOL OUTLINE This is a randomized double blind placebo controlled parallel study

Patients are randomized to receive either L-baclofen or placebo orally at increasing daily doses for 1 week Patients then continue to receive the maximum dosage acceptable for a 1 week maintenance period

Patients thereafter may enroll in a long term open label study with L-baclofen

Patients are followed at 1 3 6 9 and 12 months

Completion date provided represents the completion date of the grant per OOPD records

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
UPSOM-FDR000914 None None None
UPSOM-950686-9608 None None None